SOPHiA GENETICS SA (NASDAQ:SOPH) Given Average Recommendation of "Hold" by Brokerages

Key Points

• Analyst sentiment is mixed: Five brokerages give SOPHiA GENETICS an average “Hold” rating, with three buys, one hold and one sell. The average 12-month price target is $10, above the reported share price of $7.61.
• Quarterly results fell short on earnings: The company reported a loss of $0.26 per share versus the consensus loss estimate of $0.21, although revenue of $23.31 million exceeded expectations of $21.72 million. Analysts expect a full-year loss of $0.77 per share.
• Insiders have been selling shares: Company insiders sold 342,592 shares worth approximately $2.21 million over the past three months, while institutional investors own 31.59% of the stock.

Shares of SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) have been assigned an average recommendation of "Hold" from the five brokerages that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $10.00.

SOPH has been the subject of several recent analyst reports. HC Wainwright increased their price target on SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a "buy" rating in a report on Wednesday, August 5th. BTIG Research lifted their price target on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the company a "buy" rating in a research note on Wednesday, August 5th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. Finally, Zacks Research upgraded shares of SOPHiA GENETICS to a "hold" rating in a research note on Tuesday, July 21st.

SOPHiA GENETICS Stock Down 0.9%

Shares of SOPHiA GENETICS stock opened at $7.61 on Friday. The stock has a market cap of $638.40 million, a PE ratio of -6.62 and a beta of 0.98. SOPHiA GENETICS has a 12 month low of $3.10 and a 12 month high of $8.98. The business has a fifty day simple moving average of $6.98 and a 200 day simple moving average of $5.67. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 0.58.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.21) by ($0.05). The firm had revenue of $23.31 million during the quarter, compared to analyst estimates of $21.72 million. SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. Research analysts predict that SOPHiA GENETICS will post -0.77 EPS for the current year.

Insider Activity

In other news, CEO Jurgi Camblong sold 50,069 shares of the stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $5.80, for a total value of $290,400.20. Following the transaction, the chief executive officer directly owned 3,601,493 shares of the company's stock, valued at $20,888,659.40. This represents a 1.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Zhenyu Xu sold 17,000 shares of the stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $7.29, for a total transaction of $123,930.00. Following the completion of the transaction, the insider directly owned 590,887 shares in the company, valued at approximately $4,307,566.23. This represents a 2.80% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 342,592 shares of company stock worth $2,205,587 over the last three months. Insiders own 4.88% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Squarepoint Ops LLC bought a new position in shares of SOPHiA GENETICS in the third quarter worth $49,000. First Dallas Securities Inc. bought a new position in SOPHiA GENETICS in the 1st quarter valued at approximately $50,000. Quadrature Capital Ltd bought a new position in shares of SOPHiA GENETICS during the fourth quarter valued at $54,000. XTX Topco Ltd bought a new position in SOPHiA GENETICS during the 4th quarter worth $55,000. Finally, Susquehanna International Group LLP bought a new position in shares of SOPHiA GENETICS during the third quarter worth about $88,000. 31.59% of the stock is owned by institutional investors.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.